Miriam Kidron's most recent trade in Oramed Pharmaceuticals, Inc was a trade of 74,000 Common Stock done . Disclosure was reported to the exchange on Feb. 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 74,000 | 1,074,666 (6%) | 0% | 0 | Common Stock | |
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 66,667 | 1,193,333 (6%) | 0% | 0 | Common Stock | |
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 52,000 | 1,126,666 (6%) | 0% | 0 | Common Stock | |
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 207,000 | 1,000,666 (5%) | 1% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2024 | 30,000 | 793,666 (4%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Kidron Miriam | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 295,500 | 763,666 (4%) | 1% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 53,500 | 468,166 (2%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2023 | 213,000 | 414,666 (2%) | 1% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.01 per share. | 14 Mar 2023 | 100,000 | 201,666 (1%) | 0% | 2.0 | 201,000 | Common Stock |
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 84,000 | 301,666 (1%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 34,000 | 217,666 (1%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 72,000 | 72,000 | - | - | Stock Option (right to buy) | |
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 42,000 | 183,666 (1%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2021 | 66,666 | 141,666 (0%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals, Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) |